Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.50% | -12.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.50% | -12.56% | |||
| Cost of Revenue | 18.63% | -11.00% | |||
| Gross Profit | 3.15% | -13.60% | |||
| SG&A Expenses | -0.20% | 28.45% | |||
| Depreciation & Amortization | 0.00% | -3.53% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.80% | 6.29% | |||
| Operating Income | 29.71% | -128.24% | |||
| Income Before Tax | 12.43% | -3.21% | |||
| Income Tax Expenses | -88.03% | 132.77% | |||
| Earnings from Continuing Operations | 15.01% | -20.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.01% | -20.27% | |||
| EBIT | 29.71% | -128.24% | |||
| EBITDA | 73.97% | -91.21% | |||
| EPS Basic | 16.00% | -19.93% | |||
| Normalized Basic EPS | 17.05% | -2.53% | |||
| EPS Diluted | 16.49% | -20.63% | |||
| Normalized Diluted EPS | 17.05% | -2.53% | |||
| Average Basic Shares Outstanding | 1.18% | 0.29% | |||
| Average Diluted Shares Outstanding | 1.18% | 0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||